Andros Pharmaceuticals Co (ROCO:6917) ROC (Joel Greenblatt) %: -62.15% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
42 GF Score
Price NT$32.05
GF Value NT$166.70
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co ROC (Joel Greenblatt) %?

Andros Pharmaceuticals Co ROCO:6917 -0.47% 42 ROC (Joel Greenblatt) % is -62.15% as of Dec. 2025. GuruFocus rates ROCO:6917 with a GF Score™ of 42/100 and a GF Value™ of NT$166.70 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,320 Biotechnology companies, Andros Pharmaceuticals Co ranks better than 53.94% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Andros Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -62.15%.

The historical rank and industry rank for Andros Pharmaceuticals Co's ROC (Joel Greenblatt) % or its related term are showing as below:

ROCO:6917' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -278.85   Med: -113.57   Max: -74.47
Current: -218.54

During the past 7 years, Andros Pharmaceuticals Co's highest ROC (Joel Greenblatt) % was -74.47%. The lowest was -278.85%. And the median was -113.57%.

ROCO:6917's ROC (Joel Greenblatt) % is ranked better than
53.94% of 1320 companies
in the Biotechnology industry
Industry Median: -300.315 vs ROCO:6917: -218.54

Andros Pharmaceuticals Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -31.30% per year.


Andros Pharmaceuticals Co  (ROCO:6917) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Andros Pharmaceuticals Co ROC (Joel Greenblatt) % Related Terms


Andros Pharmaceuticals Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co ROC (Joel Greenblatt) % Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -88.26 -113.57 -217.84 -278.85 -220.13

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -288.49 -236.30 -344.55 -356.03 -62.15

ROCO:6917 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Andros Pharmaceuticals Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Andros Pharmaceuticals Co ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's ROC (Joel Greenblatt) % falls into.


ROCO:6917
42GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.019 + 0.892 + 10.628) - (14.575 + 0 + 0.488)
=-3.524

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.5 + 1.534 + 10.124) - (18.882 + 0 + 3.445)
=-10.169

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Andros Pharmaceuticals Co for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.304/( ( (24.72 + max(-3.524, 0)) + (21.308 + max(-10.169, 0)) )/ 2 )
=-14.304/( ( 24.72 + 21.308 )/ 2 )
=-14.304/23.014
=-62.15 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -62.15% mean?
Andros Pharmaceuticals Co (ROCO:6917) has a ROC (Joel Greenblatt) % of -62.15% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Andros Pharmaceuticals Co and its competitors. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #608 out of 1320 companies in the Biotechnology industry, placing it in the top 46.1%.
Is Andros Pharmaceuticals Co's ROC (Joel Greenblatt) % too high?
Andros Pharmaceuticals Co's current ROC (Joel Greenblatt) % is -62.15%. Based on the distribution chart, Andros Pharmaceuticals Co ranks #608 out of 1320 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Andros Pharmaceuticals Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #608 out of 1320 companies for ROC (Joel Greenblatt) %. This puts Andros Pharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current ROC (Joel Greenblatt) % is -62.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$166.70, compared to a current price of NT$32.05 — trading 80.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is -62.15%. Andros Pharmaceuticals Co's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current ROC (Joel Greenblatt) % is -62.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$32.05 is trading 80.8% below its estimated GF Value™ of NT$166.70. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • ROC (Joel Greenblatt) %: -62.15%
  • GF Value™: NT$166.70 vs. price of NT$32.05 (80.8% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
42GF Score

Get the complete analysis for ROCO:6917

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.05
Price
NT$166.70
GF Value